DK2829283T3 - Fremgangsmåde til behandling af kræft ved brug af immunotoxin - Google Patents

Fremgangsmåde til behandling af kræft ved brug af immunotoxin Download PDF

Info

Publication number
DK2829283T3
DK2829283T3 DK14172801.4T DK14172801T DK2829283T3 DK 2829283 T3 DK2829283 T3 DK 2829283T3 DK 14172801 T DK14172801 T DK 14172801T DK 2829283 T3 DK2829283 T3 DK 2829283T3
Authority
DK
Denmark
Prior art keywords
immunotoxin
cancer
antibody
tumor
treatment
Prior art date
Application number
DK14172801.4T
Other languages
English (en)
Inventor
Uwe Zangenmeister-Wottke
Paolo Claudio Di
Dominique Christine Tschudi
Nicholas Ronald Glover
Dimitri Peter Fitsialos
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Application granted granted Critical
Publication of DK2829283T3 publication Critical patent/DK2829283T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (16)

1. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af hoved- og nakke-pladecellecarcinom ved indgivelse intratumoralt eller peri-tumoralt direkte til kræftstedet, og hvori immunotoksinet omfatter: (a) et antistof eller antistoffragment, som binder til Ep-CAM på den tilknyttede kræftcelle; (b) et toksin, som er cytotoksisk for kræftcellen.
2. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af hoved- og nakke-pladecellecarcinom ifølge krav 1, hvori antistoffet eller antistoffragmentet er murint, humaniseret eller et kimærisk antistof eller antistoffragment.
3. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af hoved- og nakke-pladecellecarcinom ifølge krav 1 eller 2, hvori antistoffet eller antistoffragmentet er Fab, Fab’, (Fab’)2, scFv eller dsFv fragment, eventuelt hvor antistoffragmentet er et scFv fragment.
4. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af hoved- og nakke-pladecellecarcinom ifølge krav 1, hvori antistoffet eller antistoffragmentet omfatter kortkædede-CDR'er som defineret af SEQ ID NO: 4-6 og langkædede CDR'er som defineret af SEQ ID NO: 7-9.
5. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af hoved- og nakke-pladecellecarcinom ifølge krav 1, hvori immunotoksinet består af aminosyresekvensen som defineret af SEQ ID NO: 2.
6. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af hoved- og nakke-pladecellecarcinom ifølge krav 1, hvori antistoffragmentet består af aminosyresekvensen som defineret af SEQ ID NO: 3 eller en variant deraf.
7. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af hoved- og nakke-pladecellecarcinom ifølge ethvert af krav 1 til 6, hvori antistoffet eller fragmentet binder til human Ep-CAM med en dissociationskonstant (Kd) på mindre end 2,0 x 10~8.
8. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af hoved- og nakke-pladecellecarcinom ifølge ethvert af krav 1 til 7, hvori toksinet omfatter et middel der virker til opbrydning af DNA, et middel der virker til opbrydning af tubulin, et alkyleringsmiddel, et antimitotisk middel, en topoisomerase I-hæmmer, en topoisomerase Π-hæmmer, en RNA eller DNA antimetabolit, vinblastin-sulfat eller et ribosom-inaktiverende polypeptid, eventuelt hvor toksinet er udvalgt blandt gmppen bestående af gelonin, bouganin, saporin, ricin, ricin A-kæde, bryodin, difteri og restrictocin, især hvori toksinet er Pseudomonas exotoxin A eller en variant deraf.
9. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af hoved- og nakke-pladecellecarcinom ifølge ethvert af krav 1 til 8, ydereligere omfattende anvendelsen af yderligere kræftterapier til samtidig, separat eller sekventiel behandling eller forebyggelse af hoved- og nakke-pladecellecarcinom, hvori de yderligere kræftterapier er udvalgt blandt grupperne bestående af: (A) et eller flere cytokiner herunder en lymfokin, tumornekrosefaktor, tumor-nekrosefaktorlignende cytokin, lymfotoxin, interferon, makrofaginflammato-risk protein, granulocyt-monocyt-kolonistimuleringsfaktor og interleukin og en variant deraf, herunder et farmaceutisk acceptabelt salt deraf; (B) antibiotika herunder bleomycin; nervevækstfaktor, blodpladeafledt vækstfaktor; antihistaminiske midler; eller anti-kvalme midler; (C) hormonterapier, herunder flutamid, tamoxifen, leuprolidacetat, dexame-thason, retinoid, betamethason, cortisol, cortison, prednison, dehydrotestoste-ron, glucocorticoid, mineralocorticoid, østrogen, testosteron eller progestin; (D) strålebehandling, eventuelt i kombination med cisplatin, fluorouracil, carboplatin og/eller paclitaxel; kirurgi og/eller kemoterapi; (E) genterapi; (F) en eller flere af terapeutiske midler, herunder bleomycin, carboplatin, cis- platin, cyclophosphamid, cytarabin, dacarbazin, docetaxel, fludarabin, flu-orouracil, flutamid, gemcitabin, hydroxyurea, interferon-alfa, interferon-beta, interferon-gamma, interleukin-2, methotrexat, mitomyciner, oxaliplatin, pac-litaxel, tamoxifen, vineristin, gemtuzumab, 6-mercaptopurin, 6-thioguanin, 5-fluorouracil, temozamid, hexamethylmelamin, nukleosidanaloger, camp-tothecin, topotecan, irinotecan, vincaalkyloider, antracycliner, leuprolidace-tat, rituximab, retinoin, og vinorelbine; (G) mindst en anden immunoterapi herunder rituximab, gemtuzumab og trastuzumab; eller (H) vinorelbintartrat og/eller paclitaxel.
10. Effektiv mængde af et immunotoksin til anvendelse til behandling eller forebyggelse af hoved- og nakke-pladecellecarcinom ifølge et hvilket som helst af kravene 1 til 9, hvori immunotoksinet indgives i en dosis fra 10 til 3000 pg immunotok-sin/tumor/dag, eventuelt i en dosis fra 20 til 1240 pg immunotoxin/tumor/dag.
11. Effektiv mængde af et immunotoksin til anvendelse til behandling eller forebyggelse af hoved- og nakke-pladecellecarcinom ifølge et hvilket som helst af kravene 1 til 10, hvori immunotoksinet indgives i 1-6 cyklusser, hvor hver cyklus omfatter en daglig dosis for 1 til 7 dage.
12. Kit til anvendelse ved behandling eller forebyggelse af hoved- og nakke-pladecellecarcinom omfattende en effektiv mængde af et immunotoksin omfattende (a) et antistof eller antistoffragment, som binder til Ep-CAM på den tilknyttede kræftcelle; (b) et toksin, som er cytotoksisk for kræftcellen.
13. Kit til anvendelse til behandling eller forebyggelse af hoved- og nakke-pladecellecarcinom ifølge krav 12, hvori antistoffragmentet er et Fab, Fab’, (Fab’)2, scFv eller dsFv fragment, eventuelt hvor antistoffragmentet er et scFv- ragment.
14. Kit til anvendelse til behandling eller forebyggelse af hoved- og nakke-pladecellecarcinom ifølge krav 12, hvori antistoffet eller antistoffragmentet omfatter kortkædede CDCD'er, som defineret af SEQ ID NO: 4-6 og langkædede CDR'er som defineret af SEQ ID NOS: 7-9, og hvor immunotoksinet indgives intratumoralt eller peritumoralt direkte til kræftstedet.
15. Kit til anvendelse til behandling eller forebyggelse af hoved- og nakke- pladecellecarcinom ifølge krav 12, hvori immunotoksinet består af aminosyresekven-sen som defineret af SEQ ID NO: 2, og hvor immunotoksinet indgives intratumoralt eller peritumoralt direkte til kræftstedet.
16. Kit til anvendelse til behandling eller forebyggelse af hoved- og nakke- pladecellecarcinom ifølge krav 12, hvori antistoffragmentet består af aminosyrese-kvensen som defineret af SEQ ID NO: 3 eller en variant deraf, og hvor immunotoksinet indgives intratumoralt eller peritumoralt direkte til kræftstedet.
DK14172801.4T 2003-04-30 2004-04-30 Fremgangsmåde til behandling af kræft ved brug af immunotoxin DK2829283T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46660803P 2003-04-30 2003-04-30
EP10011667.2A EP2382990B1 (en) 2003-04-30 2004-04-30 Methods for treating cancer using an immunotoxin

Publications (1)

Publication Number Publication Date
DK2829283T3 true DK2829283T3 (da) 2017-09-18

Family

ID=33418401

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10011667.2T DK2382990T3 (da) 2003-04-30 2004-04-30 Fremgangsmåder til behandling af kræft ved anvendelse af et immunotoksin
DK14172801.4T DK2829283T3 (da) 2003-04-30 2004-04-30 Fremgangsmåde til behandling af kræft ved brug af immunotoxin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10011667.2T DK2382990T3 (da) 2003-04-30 2004-04-30 Fremgangsmåder til behandling af kræft ved anvendelse af et immunotoksin

Country Status (14)

Country Link
US (6) US20070196366A1 (da)
EP (3) EP2382990B1 (da)
JP (1) JP4988333B2 (da)
CN (1) CN100417414C (da)
AU (1) AU2004234191A1 (da)
CA (2) CA2826735C (da)
DK (2) DK2382990T3 (da)
ES (2) ES2639301T3 (da)
HK (1) HK1206617A1 (da)
HU (1) HUE033533T2 (da)
IL (2) IL171643A (da)
PL (2) PL2829283T3 (da)
PT (2) PT2382990E (da)
WO (1) WO2004096271A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1918303A3 (en) 1999-04-09 2008-05-14 Universität Zürich method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
PT2382990E (pt) 2003-04-30 2014-12-29 Univ Zuerich Método para tratamento do cancro usando uma imunotoxina
US20060127399A1 (en) * 2004-09-13 2006-06-15 Defu Zeng Compositions and methods for inducing chimerism in a subject
JP2008526889A (ja) * 2005-01-10 2008-07-24 リサーチ ディベロップメント ファウンデーション 癌治療のための標的化キメラ分子
ATE530198T1 (de) * 2005-02-16 2011-11-15 Univ Zuerich Verfahren zur behandlung von krebs unter verwendung eines immunotoxins mit einer exotoxin- a-gruppierung, bei der eine furinschnittstelle durch eine von mmp-2 oder mmp-9 gespaltene krebsassoziierte proteasestelle ersetzt ist
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
JP2009520468A (ja) * 2005-12-23 2009-05-28 ヴィヴェンティア バイオテック インコーポレーティッド 融合タンパク質ライブラリーの作製法およびスクリーニング法、ならびにそれらの使用
WO2008128330A1 (en) * 2007-04-19 2008-10-30 Viventia Biotech Inc. Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
US8318472B2 (en) * 2007-09-27 2012-11-27 Viventia Biotechnologies Inc. Optimized nucleic acid sequences for the expression of VB4-845
US8110193B2 (en) * 2007-12-21 2012-02-07 City Of Hope Methods for conditioning a subject for hematopoietic cell transplantation
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
US20100055107A1 (en) * 2008-07-31 2010-03-04 Defu Zeng Methods for preventing hematological malignancies and graft versus host disease by anti-cd3 preconditioning
WO2010051635A1 (en) * 2008-11-06 2010-05-14 University Of Guelph Methods of improving the therapeutic efficacy and utility of antibody fragments
CA2745899C (en) * 2008-12-05 2015-04-28 Vuong Trieu Albumin binding peptide-mediated disease targeting
EP3385279B1 (en) 2009-03-20 2020-02-26 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2011031441A1 (en) * 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
CN102844443B (zh) 2009-09-21 2014-08-06 保罗·沃尔菲什 用于甲状腺癌诊断和治疗的方法和组合物
TWI494566B (zh) 2009-09-24 2015-08-01 Univ California 膀胱癌特異性配體肽
WO2011047135A2 (en) * 2009-10-14 2011-04-21 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treating bladder cancer
MX2012006560A (es) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
WO2011137513A1 (en) 2010-05-04 2011-11-10 Paul Walfish Method for the diagnosis of epithelial cancers by the detection of epicd polypeptide
JP6159660B2 (ja) * 2010-09-22 2017-07-05 アムジエン・インコーポレーテツド 担体としての免疫グロブリンおよびその使用
IL297229A (en) 2012-01-27 2022-12-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
EP2986324A4 (en) * 2013-04-12 2016-12-14 Viventia Bio Inc COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA
HUE046673T2 (hu) 2013-10-02 2020-03-30 Viventia Bio Inc Anti-EpCAM antitestek és alkalmazási eljárások
WO2016145349A1 (en) * 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
US10583198B2 (en) 2015-03-12 2020-03-10 Viventia Bio Inc. Dosing strategies for targeting EPCAM positive bladder cancer
WO2018174053A1 (ja) * 2017-03-22 2018-09-27 学校法人兵庫医科大学 標準化学療法に不応又は不耐で治癒切除不能な進行又は再発癌患者の治療のための医薬
WO2018220467A1 (en) * 2017-05-30 2018-12-06 Foroogh Nejatollahi Anti-muc18 human immunotoxin and applications thereof
CN111417646B (zh) * 2017-07-10 2024-04-19 斯坦福国际研究院 用于治疗癌症的肽皂草素缀合物
CN108122613B (zh) * 2018-01-15 2022-04-01 北京颐圣智能科技有限公司 基于健康预测模型的健康预测方法和装置
CN110194803B (zh) * 2019-06-26 2021-01-05 上海科棋药业科技有限公司 一种靶向EpCAM的嵌合抗原受体及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4677070A (en) 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5082927A (en) 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4933288A (en) 1986-11-21 1990-06-12 Cetus Corporation Use of a modified soluble Pseudomonas exotoxin A in immunoconjugates
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5621078A (en) 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
US5458878A (en) 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
EP0509056A4 (en) 1990-01-02 1993-02-17 Us Health Target-specific, cytotoxic, recombinant pseudomonas exotoxin
DE69131449T2 (de) 1990-05-11 1999-11-25 Us Health Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
CA2136724A1 (en) 1992-06-18 1993-12-23 Ira H. Pastan Recombinant pseudomonas exotoxin with increased activity
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE69629580D1 (de) 1995-10-13 2003-09-25 Us Gov Health & Human Serv Immunotoxin enthaltend ein disulfid-stabilisiertes antikörperfragment
IL116559A (en) 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
JP2000511050A (ja) 1996-05-31 2000-08-29 メディジーン・アクチェンゲゼルシャフト 機能性分子表面の生成、スクリーニング、および展開のための新規の合成タンパク質の構造の鋳型
EP0941334B1 (en) 1996-11-06 2004-06-02 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Protease-activatable pseudomonas exotoxin a-like proproteins
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
US6180341B1 (en) 1997-05-01 2001-01-30 Board Of Regents, The Universiry Of Texas System In vitro scanning saturation mutagenesis of proteins
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
EP0975762B1 (en) 1997-06-06 2011-10-05 PanGenetics B.V. Type-1 ribosome-inactivating protein
US20030054012A1 (en) 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
EP1037927B1 (en) * 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ES2329959T5 (es) 1998-12-10 2013-12-18 Bristol-Myers Squibb Company Armazones de proteína para miméticos de anticuerpo y otras proteínas de unión
EP1918303A3 (en) 1999-04-09 2008-05-14 Universität Zürich method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
GB9911569D0 (en) * 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
JP2004526419A (ja) 2000-10-16 2004-09-02 フィロス インク． 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CN100503639C (zh) 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
US20030148950A1 (en) 2001-10-09 2003-08-07 Li Xin Kringle domain 1 of human hepatocyte growth factor and uses therefor
BR0213303A (pt) * 2001-10-15 2005-06-07 Immunomedics Inc Proteìnas de ligação de alvejamento direto
US20040022726A1 (en) 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
SI21272A (sl) 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Sintetski gen za humani granulocitne kolonije stimulirajoči dejavnik za ekspresijo v E. coli
CA2424255A1 (en) 2003-03-26 2004-09-26 Claudio Di Paolo Immunotoxins
PT2382990E (pt) 2003-04-30 2014-12-29 Univ Zuerich Método para tratamento do cancro usando uma imunotoxina
PT1737961E (pt) 2004-03-19 2013-08-26 Merck Patent Gmbh Proteínas buganina modificadas, citotoxinas e métodos e utilizações das mesmas
EP2927322A1 (en) 2004-06-10 2015-10-07 Viventia Bio Inc. Tumor specific antibody
US20090171317A1 (en) 2006-03-10 2009-07-02 Ebrahim Versi Self-Catheterization Device To Administes Compounds To The Bladder
CA2668017A1 (en) 2006-10-30 2008-05-08 Viventia Biotech Inc. Improved conjugates
WO2008128330A1 (en) 2007-04-19 2008-10-30 Viventia Biotech Inc. Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
US8318472B2 (en) 2007-09-27 2012-11-27 Viventia Biotechnologies Inc. Optimized nucleic acid sequences for the expression of VB4-845
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
RU2011145038A (ru) 2009-04-08 2013-05-20 Дойчес Кребсфоршунгсцентрум Несущие аматоксины мишень-связывающие молекулы для лечения рака
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
WO2011116387A1 (en) 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
CN107080847A (zh) 2011-06-24 2017-08-22 森彻斯有限公司 细胞外靶向药物缀合物
EP2986324A4 (en) 2013-04-12 2016-12-14 Viventia Bio Inc COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA
HUE046673T2 (hu) 2013-10-02 2020-03-30 Viventia Bio Inc Anti-EpCAM antitestek és alkalmazási eljárások
US10583198B2 (en) 2015-03-12 2020-03-10 Viventia Bio Inc. Dosing strategies for targeting EPCAM positive bladder cancer
WO2017040801A2 (en) 2015-09-02 2017-03-09 Viventia Bio Inc. Methods for making and using an immunoconjugate for the treatment of cancer

Also Published As

Publication number Publication date
EP2382990A1 (en) 2011-11-02
CN1816352A (zh) 2006-08-09
DK2382990T3 (da) 2014-12-15
US20100249039A1 (en) 2010-09-30
US20210040203A1 (en) 2021-02-11
IL171643A (en) 2011-08-31
US20140178417A1 (en) 2014-06-26
WO2004096271A1 (en) 2004-11-11
HK1206617A1 (en) 2016-01-15
US8545840B2 (en) 2013-10-01
EP2829283B1 (en) 2017-06-07
IL213621A (en) 2013-12-31
US20070196366A1 (en) 2007-08-23
JP4988333B2 (ja) 2012-08-01
PL2382990T3 (pl) 2015-04-30
ES2639301T3 (es) 2017-10-26
CA2524124A1 (en) 2004-11-11
PT2829283T (pt) 2017-09-08
US11713352B2 (en) 2023-08-01
EP1635868A1 (en) 2006-03-22
IL213621A0 (en) 2011-07-31
EP2829283A1 (en) 2015-01-28
PT2382990E (pt) 2014-12-29
CA2524124C (en) 2014-03-25
CN100417414C (zh) 2008-09-10
EP2382990B1 (en) 2014-09-17
CA2826735A1 (en) 2004-11-11
US11713351B2 (en) 2023-08-01
ES2526219T3 (es) 2015-01-08
US10858429B2 (en) 2020-12-08
JP2006526576A (ja) 2006-11-24
US9259484B2 (en) 2016-02-16
US20210317203A1 (en) 2021-10-14
AU2004234191A1 (en) 2004-11-11
HUE033533T2 (en) 2017-12-28
PL2829283T3 (pl) 2017-12-29
US20160199507A1 (en) 2016-07-14
CA2826735C (en) 2019-06-04

Similar Documents

Publication Publication Date Title
US11713351B2 (en) Immunotoxin for treating cancer
WO2008052322A1 (en) Immunotoxγn fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers
US20160060352A1 (en) Compositions and methods for detection and treatment of hepatocellular carcinoma
WO2015048901A1 (en) Anti-epcam antibodies and methods of use
AU2008316224A1 (en) Antibodies against a cancer-associated epitope of variant HnRNPG and uses thereof
EP1848462B1 (en) Methods for treating cancer using an immunotoxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer-associated protease site cleaved by mmp-2 or mmp-9
WO2016187585A1 (en) Deimmunized linker and methods of use
WO2016187571A2 (en) Her2 immunotoxins and methods of using the same